Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents, Patent Applications Awarded to Exiqon, Alnylam, Applied Biosystems, and More

Premium

Title: Methods for Quantification of microRNAs and Small Interfering RNAs

Patent Number: 8,192,937

Filed: April 7, 2005

Lead Inventor: Nana Jacobson, Exiqon

“The invention relates to ribonucleic acids, probes, and methods for detection, quantification … [and] monitoring the expression of mature microRNAs and small interfering RNAs,” the patent's abstract states. “The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs [and] mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts. ... The invention furthermore relates to methods for detection, quantification [and] monitoring the expression of deoxy nucleic acids.”


Title: Methods for Quantifying microRNA Precursors

Patent Number: 8,192,938

Filed: Feb. 24, 2006

Inventor: Thomas Schmittgen, Ohio State University

The invention, the patent's abstract states, comprises “methods, reagents, kits, and compositions for detecting microRNA precursors in a biological sample. The method uses gene-specific primers and reverse transcriptase to convert the primary miRNA precursors and pre-miRNA precursors to cDNA. The method also uses amplification reactions using gene-specific forward and reverse primers that are targeted to the hairpin sequence of pri- and pre-microRNA precursors to detect the expression levels of both the pri- and the pre-microRNAs.”


Title: Amplification and Detection of Ribonucleic Acid

Patent Number: 8,192,941

Filed: July 14, 2010

Inventor: Scott Kuersten, Applied Biosystems (Life Technologies)

The patent, its abstract states, claims “compositions, methods, and kits for detecting one or more species of RNA molecules. ... In one embodiment, a first adaptor and a second adaptor are ligated to the RNA molecule using a polypeptide comprising double-strand specific RNA ligase activity, without an intervening purification step. The ligated product is reverse transcribed, then at least some of the ribonucleosides in the reverse transcription product are removed. Primers are added and amplified products are generated.

“In certain embodiments, the sequence of at least part of at least one species of amplified product is determined and at least part of the corresponding RNA molecule is determined,” the abstract notes. “In some embodiments, at least some of the amplified product species are detected, directly or indirectly, allowing the presence and/or quantity of the RNA molecule of interest to be determined.”


Title: Compositions Comprising Cardiac Stem Cells Over-Expressing Specific microRNAs and Methods of Their Use in Repairing Damaged Myocardium

Patent Number: 8,193,161

Filed: June 9, 2009

Lead Inventor: Toru Hosoda, New York Medical College

“The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis,” according to the patent's abstract.
“In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed.”


Title: Compositions and Methods for siRNA Inhibition of ICAM-1

Patent Number: 8,193,163

Filed: Nov. 22, 2010

Lead Inventor: Samuel Reich, University of Pennsylvania (Opko Health)

The patent, its abstract states, claims “RNA interference using small interfering RNAs ... specific for the ICAM-1 gene. ... Diseases [that] involve ICAM-1-mediated cell adhesion, such as inflammatory and autoimmune diseases, diabetic retinopathy, and other complications arising from type I diabetes, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs.”


Title: Cancer Therapy Using Bcl-XL-Specific siNA

Patent Number: 8,193,333

Filed: June 22, 2007

Lead Inventor: Laurent Poulain, Francois Baclesse Center

“The invention relates to a double-stranded short interfering nucleic acid molecule specific to the Bcl-XL transcript, comprising a sense and an antisense region, wherein the … the antisense region comprises a nucleotide sequence that is complementary to the sense region, and its use for treating cancer,” the patent's abstract states.


Title: siRNA Targeting Spleen Tyrosine Kinase

Application Number: 20120135892

Filed: Dec. 6, 2011

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes.”


Title: Hybrid Interfering RNA

Application Number: 20120136040

Filed: Oct. 11, 2011

Lead Inventor: Jo Ann Milner, University of York

“The invention relates to a hybrid interfering RNA molecule comprising a duplex RNA and a single-stranded DNA molecule and its use in the ablation of mRNA and in polymerase chain reactions,” the patent application's abstract states.


Title: Carbohydrate Conjugates as Delivery Agents for Oligonucleotides

Application Number: 20120136042

Filed: Dec. 14, 2011

Lead Inventor: Muthiah Manoharan, Alnylam Pharmaceuticals

The invention, the patent application's abstract states, comprises RNAi agents with at least one subunit of a predefined formula the formula.


Title: Compositions and Methods of Inhibiting NADPH Oxidase Expression

Application Number: 20120136044

Filed: Feb. 7, 2012

Lead Inventor: Hagar Kalinski, Quark Pharmaceuticals

“The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of a NOX gene,” according to the patent application's abstract. “The invention also relates to a pharmaceutical composition comprising the compound or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The … invention also contemplates a method of treating or preventing the incidence or severity of various diseases or conditions associated with NOX gene comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient.”


Title: siRNA Targeting Catenin, Beta-1

Application Number: 20120136144

Filed: Oct. 30, 2007

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

“Efficient sequence-specific gene silencing is possible through the use of siRNA technology,” the patent application's abstract states. “By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed, including those directed to nucleotide sequences for CTNNB1.”


Title: Compositions and Methods for Inhibiting Expression of Eg5 Gene

Application Number: 20120136145

Filed: June 21, 2011

Lead Inventor: David Bumcrot, Alnylam Pharmaceuticals

“The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of the Eg5 gene, comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene,” according to the patent application's abstract. “The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.”

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.